Scientific article
Open access

PET Imaging in Dementia : Mini-Review and Canadian Perspective for Clinical Use

Publication date2024-03-04
First online date2024-03-04

PET imaging is increasingly recognized as an important diagnostic tool to investigate patients with cognitive disturbances of possible neurodegenerative origin. PET with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), assessing glucose metabolism, provides a measure of neurodegeneration and allows a precise differential diagnosis among the most common neurodegenerative diseases, such as Alzheimer's disease, frontotemporal dementia or dementia with Lewy bodies. PET tracers specific for the pathological deposits characteristic of different neurodegenerative processes, namely amyloid and tau deposits typical of Alzheimer's Disease, allow the visualization of these aggregatesin vivo. [18F]FDG and amyloid PET imaging have reached a high level of clinical validity and are since 2022 investigations that can be offered to patients in standard clinical care in most of Canada.This article will briefly review and summarize the current knowledge on these diagnostic tools, their integration into diagnostic algorithms as well as perspectives for future developments.

  • Alzheimer’s disease
  • DOPA
  • Frontotemporal lobar degeneration
  • PET
  • Parkinsonism
  • Amyloid
  • Dopamine transporters
  • Glucose metabolism
  • Tau
Citation (ISO format)
JUENGLING, Freimut et al. PET Imaging in Dementia : Mini-Review and Canadian Perspective for Clinical Use. In: Canadian journal of neurological sciences, 2024, p. 1–13. doi: 10.1017/cjn.2024.31
Main files (1)
Article (Published version)
ISSN of the journal0317-1671

Technical informations

Creation03/22/2024 4:12:10 PM
First validation05/24/2024 6:39:42 AM
Update time05/24/2024 6:39:42 AM
Status update05/24/2024 6:39:42 AM
Last indexation05/24/2024 6:40:02 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack